You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydroergotamine
Accession NumberDB00320  (APRD00476)
TypeSmall Molecule
GroupsApproved
DescriptionA 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]
Structure
Thumb
Synonyms
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman
9,10-dihydro-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
9,10-dihydroergotamine
Dihidroergotamina
Dihydroergotamin
Dihydroergotamine
Dihydroergotaminum
Diidroergotamina
External Identifiers
  • MAP-0004
  • MAP0004
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
D.H.E. 45injection, solution1 mg/mLintramuscular; intravenous; subcutaneousValeant Pharmaceuticals North America2001-10-03Not applicableUs
Dihydroergotamine (dhe), 1mg/mlliquid1 mgintramuscular; intravenous; subcutaneousSterimax Inc1946-12-31Not applicableCanada
Dihydroergotamine Mesylatespray4 mg/mLnasalOceanside Pharmaceuticals2013-03-18Not applicableUs
Dihydroergotamine Mesylate Injection USPliquid1 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1999-12-23Not applicableCanada
Migranalspray4 mg/mLnasalValeant Pharmaceuticals North America LLC1997-12-08Not applicableUs
Migranal Nasal Spray 4mg/mlliquid4 mgnasalSterimax Inc1996-11-05Not applicableCanada
PMS-dihydroergotamineliquid1 mgintramuscular; intravenous; subcutaneousPharmascience IncNot applicableNot applicableCanada
PMS-dihydroergotamineliquid4 mgnasalPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dihydroergotamine Mesylateinjection, solution1 mg/mLintramuscular; intravenous; subcutaneousPaddock Laboratories, LLC2003-04-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DihydergotSandoz
ErgontSigmapharm
ErgotoninNot Available
IkaranPierre Fabre
OrstanormAmdipharm
VerladynVerla
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dihydroergotamine mesylate
6190-39-2
Thumb
  • InChI Key: ADYPXRFPBQGGAH-UMYZUSPBSA-N
  • Monoisotopic Mass: 679.267584474
  • Average Mass: 679.79
DBSALT000997
Dihydroergotamine tartrate
5989-77-5
Thumb
  • InChI Key: FXDJFTCVYTUARH-YZPGULDNSA-N
  • Monoisotopic Mass: 2483.134315159
  • Average Mass: 2484.842
DBSALT001066
Categories
UNII436O5HM03C
CAS number511-12-6
WeightAverage: 583.6774
Monoisotopic: 583.279469319
Chemical FormulaC33H37N5O5
InChI KeyInChIKey=LUZRJRNZXALNLM-JGRZULCMSA-N
InChI
InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[[email protected]](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgotamines, dihydroergotamines, and derivatives
Alternative Parents
Substituents
  • Ergotamine
  • Dihydroergotamine
  • Hybrid peptide
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 3-piperidinecarboxamide
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Piperidine
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
PharmacodynamicsDihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
Mechanism of actionTwo theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Related Articles
AbsorptionInterpatient variable and may be dependent on the administration technique
Volume of distribution
  • 800 L
Protein binding93% (to plasma proteins)
Metabolism

Hepatic

Route of eliminationThe major excretory route of dihydroergotamine is via the bile in the feces. Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.
Half life9 hours
Clearance
  • 1.5 L/min
ToxicitySide effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8348
Blood Brain Barrier-0.9817
Caco-2 permeable-0.7956
P-glycoprotein substrateSubstrate0.8223
P-glycoprotein inhibitor IInhibitor0.556
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.8229
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7227
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.712
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.591
Ames testNon AMES toxic0.897
CarcinogenicityNon-carcinogens0.9549
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.9503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9365
hERG inhibition (predictor II)Non-inhibitor0.5788
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Bedford laboratories
  • Paddock laboratories inc
Packagers
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous; subcutaneous1 mg
Injection, solutionintramuscular; intravenous; subcutaneous1 mg/mL
Spraynasal4 mg/mL
Liquidnasal4 mg
Prices
Unit descriptionCostUnit
D.H.E. 45 1 mg/ml Solution 1ml Ampule124.61USD ampule
D.H.E. 45 1 mg/ml ampul120.88USD ml
Migranal 4 mg/ml Solution 1ml Glass Container94.46USD container
Migranal nasal spray90.83USD ml
D.h.e.45 1 mg/ml ampul54.46USD ml
Dihydroergotamine 1 mg/ml am38.0USD ml
Dihydroergotamine Mesylate 1 mg/ml Solution 1ml Ampule36.4USD ampule
Migranal 4 mg/ml Spray11.17USD spray
Dihydroergotamine (Dhe) 1 mg/ml4.18USD ml
Dihydroergotamine Mesylate 1 mg/ml3.9USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5169849 No1992-12-082009-12-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.229 mg/mLALOGPS
logP3.04ALOGPS
logP2.71ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity159.39 m3·mol-1ChemAxon
Polarizability63.3 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02CA51N02CA01
AHFS Codes
  • 12:16.00
PDB EntriesNot Available
FDA labelDownload (412 KB)
MSDSDownload (53.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Dihydroergotamine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Dihydroergotamine can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Dihydroergotamine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Dihydroergotamine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Dihydroergotamine.
AcebutololAcebutolol may increase the vasoconstricting activities of Dihydroergotamine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dihydroergotamine.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Dihydroergotamine.
AcepromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Dihydroergotamine.
AcetophenazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Dihydroergotamine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Dihydroergotamine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dihydroergotamine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Dihydroergotamine.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Dihydroergotamine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dihydroergotamine.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Dihydroergotamine.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Dihydroergotamine.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Dihydroergotamine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dihydroergotamine.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Dihydroergotamine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dihydroergotamine.
AlmotriptanDihydroergotamine may increase the vasoconstricting activities of Almotriptan.
AlogliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Dihydroergotamine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Dihydroergotamine.
Alpha-1-proteinase inhibitorThe serum concentration of Dihydroergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dihydroergotamine.
AlprenololAlprenolol may increase the vasoconstricting activities of Dihydroergotamine.
AlprenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Dihydroergotamine.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Dihydroergotamine.
AmineptineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Dihydroergotamine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Dihydroergotamine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Dihydroergotamine.
AmisulprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Dihydroergotamine.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Dihydroergotamine.
AmoxapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amperozide.
AmprenavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Dihydroergotamine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Dihydroergotamine.
Antithrombin III humanThe serum concentration of Dihydroergotamine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dihydroergotamine.
ApomorphineDihydroergotamine may increase the vasoconstricting activities of Apomorphine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Dihydroergotamine.
AprepitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Dihydroergotamine.
AprotininThe serum concentration of Dihydroergotamine can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Dihydroergotamine can be increased when it is combined with Argatroban.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Dihydroergotamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.
ArotinololArotinolol may increase the vasoconstricting activities of Dihydroergotamine.
ArotinololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dihydroergotamine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.
AsenapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Dihydroergotamine.
AsunaprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Dihydroergotamine.
AtenololAtenolol may increase the vasoconstricting activities of Dihydroergotamine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Dihydroergotamine.
AtomoxetineThe metabolism of Dihydroergotamine can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Dihydroergotamine.
AvanafilThe metabolism of Avanafil can be decreased when combined with Dihydroergotamine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Dihydroergotamine.
AzaperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Azaperone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Dihydroergotamine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Dihydroergotamine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Dihydroergotamine.
BatimastatThe serum concentration of Dihydroergotamine can be increased when it is combined with Batimastat.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Dihydroergotamine.
BefunololBefunolol may increase the vasoconstricting activities of Dihydroergotamine.
BefunololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Benazepril.
BenmoxinThe metabolism of Dihydroergotamine can be decreased when combined with Benmoxin.
BenzamidineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benzamidine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Dihydroergotamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Dihydroergotamine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dihydroergotamine.
BetaxololBetaxolol may increase the vasoconstricting activities of Dihydroergotamine.
BetaxololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololBevantolol may increase the vasoconstricting activities of Dihydroergotamine.
BevantololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Dihydroergotamine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Dihydroergotamine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Dihydroergotamine.
BifeprunoxThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bifeprunox.
BisoprololBisoprolol may increase the vasoconstricting activities of Dihydroergotamine.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Dihydroergotamine.
BivalirudinThe serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Dihydroergotamine.
BopindololBopindolol may increase the vasoconstricting activities of Dihydroergotamine.
BopindololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Dihydroergotamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dihydroergotamine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dihydroergotamine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dihydroergotamine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Dihydroergotamine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Dihydroergotamine.
BromocriptineDihydroergotamine may increase the vasoconstricting activities of Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Dihydroergotamine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Dihydroergotamine.
BufuralolBufuralol may increase the vasoconstricting activities of Dihydroergotamine.
BufuralolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Dihydroergotamine.
BupranololBupranolol may increase the vasoconstricting activities of Dihydroergotamine.
BupranololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Dihydroergotamine.
BupropionThe metabolism of Bupropion can be decreased when combined with Dihydroergotamine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Dihydroergotamine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroergotamine.
BusulfanThe metabolism of Busulfan can be decreased when combined with Dihydroergotamine.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.
CabergolineCabergoline may increase the vasoconstricting activities of Dihydroergotamine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Dihydroergotamine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Dihydroergotamine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Dihydroergotamine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dihydroergotamine.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Dihydroergotamine.
CandoxatrilThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Dihydroergotamine can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Dihydroergotamine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dihydroergotamine.
CariprazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cariprazine.
CaroxazoneThe metabolism of Dihydroergotamine can be decreased when combined with Caroxazone.
CarteololCarteolol may increase the vasoconstricting activities of Dihydroergotamine.
CarteololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolCarvedilol may increase the vasoconstricting activities of Dihydroergotamine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Dihydroergotamine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Dihydroergotamine.
CeliprololCeliprolol may increase the vasoconstricting activities of Dihydroergotamine.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Dihydroergotamine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Dihydroergotamine.
CeritinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Dihydroergotamine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Dihydroergotamine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Dihydroergotamine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Dihydroergotamine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Dihydroergotamine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Dihydroergotamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Dihydroergotamine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Dihydroergotamine.
ChymostatinThe serum concentration of Dihydroergotamine can be increased when it is combined with Chymostatin.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Dihydroergotamine.
CilastatinThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Dihydroergotamine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dihydroergotamine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Dihydroergotamine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dihydroergotamine.
CirazolineDihydroergotamine may increase the hypertensive activities of Cirazoline.
CisaprideThe metabolism of Cisapride can be decreased when combined with Dihydroergotamine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dihydroergotamine.
CitalopramThe metabolism of Citalopram can be decreased when combined with Dihydroergotamine.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine.
ClarithromycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Dihydroergotamine.
ClemastineThe metabolism of Dihydroergotamine can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Dihydroergotamine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Dihydroergotamine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Dihydroergotamine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Dihydroergotamine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Dihydroergotamine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dihydroergotamine.
ClomipramineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Clomipramine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Dihydroergotamine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Dihydroergotamine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Dihydroergotamine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Dihydroergotamine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Dihydroergotamine.
ClotrimazoleThe metabolism of Dihydroergotamine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clozapine.
CobicistatThe serum concentration of Dihydroergotamine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dihydroergotamine.
CocaineThe metabolism of Cocaine can be decreased when combined with Dihydroergotamine.
CodeineThe metabolism of Codeine can be decreased when combined with Dihydroergotamine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Dihydroergotamine.
ConivaptanThe serum concentration of Dihydroergotamine can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Dihydroergotamine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Dihydroergotamine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Dihydroergotamine.
CrizotinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Crizotinib.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Dihydroergotamine.
CyamemazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyamemazine.
CyclobenzaprineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Dihydroergotamine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Dihydroergotamine.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Dihydroergotamine.
Dabigatran etexilateThe serum concentration of Dihydroergotamine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Dihydroergotamine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Dihydroergotamine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dihydroergotamine.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Dihydroergotamine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dihydroergotamine.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Dihydroergotamine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Dihydroergotamine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Dihydroergotamine.
DarunavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Dihydroergotamine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Dihydroergotamine.
DasatinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Dihydroergotamine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Dihydroergotamine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dihydroergotamine.
DeferasiroxThe serum concentration of Dihydroergotamine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Dihydroergotamine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Dihydroergotamine.
DesipramineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desipramine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Dihydroergotamine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Dihydroergotamine.
DexamethasoneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Dihydroergotamine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Dihydroergotamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dihydroergotamine.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Dihydroergotamine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Dihydroergotamine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Dihydroergotamine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dihydroergotamine.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.
DigoxinThe metabolism of Digoxin can be decreased when combined with Dihydroergotamine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dihydroergotamine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Dihydroergotamine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Dihydroergotamine.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Dihydroergotamine.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Dihydroergotamine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dihydroergotamine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Dihydroergotamine.
DolasetronDolasetron may increase the serotonergic activities of Dihydroergotamine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Dihydroergotamine.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Dihydroergotamine.
DosulepinThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Dosulepin.
DoxepinThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Dihydroergotamine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Dihydroergotamine.
DoxycyclineThe metabolism of Dihydroergotamine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dihydroergotamine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Dihydroergotamine.
DroperidolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.
DroxidopaDihydroergotamine may increase the hypertensive activities of Droxidopa.
DuloxetineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Dihydroergotamine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Dihydroergotamine.
EcabetThe serum concentration of Dihydroergotamine can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Dihydroergotamine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Dihydroergotamine can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Dihydroergotamine.
ElafinThe serum concentration of Dihydroergotamine can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dihydroergotamine.
EletriptanDihydroergotamine may increase the vasoconstricting activities of Eletriptan.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Dihydroergotamine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Dihydroergotamine.
EnalaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalapril.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Dihydroergotamine.
EnalaprilatThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Dihydroergotamine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Dihydroergotamine.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Dihydroergotamine.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Dihydroergotamine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Dihydroergotamine.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Dihydroergotamine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Dihydroergotamine.
ErgonovineErgonovine may increase the vasoconstricting activities of Dihydroergotamine.
ErgotamineDihydroergotamine may increase the hypertensive activities of Ergotamine.
ErgotamineErgotamine may increase the vasoconstricting activities of Dihydroergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Dihydroergotamine.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Dihydroergotamine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Dihydroergotamine.
Eslicarbazepine acetateThe serum concentration of Dihydroergotamine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Esmirtazapine.
EsmololEsmolol may increase the vasoconstricting activities of Dihydroergotamine.
EsmololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Dihydroergotamine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Dihydroergotamine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Dihydroergotamine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Dihydroergotamine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Dihydroergotamine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Dihydroergotamine.
EstroneThe metabolism of Estrone can be decreased when combined with Dihydroergotamine.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Dihydroergotamine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Dihydroergotamine.
EthanolThe metabolism of Ethanol can be decreased when combined with Dihydroergotamine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Dihydroergotamine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Dihydroergotamine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Dihydroergotamine.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Dihydroergotamine.
EtoposideThe metabolism of Etoposide can be decreased when combined with Dihydroergotamine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Dihydroergotamine.
EtravirineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Dihydroergotamine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Dihydroergotamine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Dihydroergotamine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dihydroergotamine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Dihydroergotamine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Dihydroergotamine.
FelodipineThe metabolism of Felodipine can be decreased when combined with Dihydroergotamine.
FencamfamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fencamfamine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Dihydroergotamine.
FentanylThe metabolism of Fentanyl can be decreased when combined with Dihydroergotamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroergotamine.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dihydroergotamine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dihydroergotamine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Dihydroergotamine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Dihydroergotamine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dihydroergotamine.
FluconazoleThe metabolism of Dihydroergotamine can be decreased when combined with Fluconazole.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Dihydroergotamine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Dihydroergotamine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Dihydroergotamine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Dihydroergotamine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dihydroergotamine.
FlupentixolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Dihydroergotamine.
FluspirileneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Dihydroergotamine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Dihydroergotamine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Dihydroergotamine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Dihydroergotamine.
FluvoxamineThe metabolism of Dihydroergotamine can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosamprenavir.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Dihydroergotamine.
FosaprepitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Dihydroergotamine can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Dihydroergotamine.
FrovatriptanDihydroergotamine may increase the vasoconstricting activities of Frovatriptan.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Dihydroergotamine.
FurazolidoneThe metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.
Fusidic AcidThe serum concentration of Dihydroergotamine can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Dihydroergotamine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Dihydroergotamine.
GeldanamycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dihydroergotamine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Dihydroergotamine.
GlipizideThe metabolism of Glipizide can be decreased when combined with Dihydroergotamine.
GlyburideThe metabolism of Glyburide can be decreased when combined with Dihydroergotamine.
GM6001The serum concentration of Dihydroergotamine can be increased when it is combined with GM6001.
GranisetronThe metabolism of Granisetron can be decreased when combined with Dihydroergotamine.
GranisetronGranisetron may increase the serotonergic activities of Dihydroergotamine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dihydroergotamine.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Dihydroergotamine.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Dihydroergotamine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Dihydroergotamine.
HaloperidolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Dihydroergotamine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Dihydroergotamine.
HirulogThe serum concentration of Dihydroergotamine can be increased when it is combined with Hirulog.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Dihydroergotamine.
HydracarbazineThe metabolism of Dihydroergotamine can be decreased when combined with Hydracarbazine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dihydroergotamine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Dihydroergotamine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Dihydroergotamine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dihydroergotamine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dihydroergotamine.
IdelalisibThe serum concentration of Dihydroergotamine can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dihydroergotamine resulting in a loss in efficacy.
IloperidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine.
ImatinibThe metabolism of Dihydroergotamine can be decreased when combined with Imatinib.
ImipramineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Imipramine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Dihydroergotamine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Dihydroergotamine.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Dihydroergotamine.
IndapamideThe metabolism of Indapamide can be decreased when combined with Dihydroergotamine.
IndenololIndenolol may increase the vasoconstricting activities of Dihydroergotamine.
IndenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Dihydroergotamine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dihydroergotamine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.
IproclozideThe metabolism of Dihydroergotamine can be decreased when combined with Iproclozide.
IproniazidThe metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Dihydroergotamine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Dihydroergotamine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isocarboxazid.
IsocarboxazidThe metabolism of Dihydroergotamine can be decreased when combined with Isocarboxazid.
IsoflurophateThe serum concentration of Dihydroergotamine can be increased when it is combined with Isoflurophate.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dihydroergotamine.
IsradipineThe metabolism of Dihydroergotamine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Dihydroergotamine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dihydroergotamine.
IvacaftorThe serum concentration of Dihydroergotamine can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Dihydroergotamine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Dihydroergotamine.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Dihydroergotamine.
IxazomibThe serum concentration of Dihydroergotamine can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Dihydroergotamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Dihydroergotamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Dihydroergotamine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Dihydroergotamine.
KetoconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Dihydroergotamine.
LabetalolLabetalol may increase the vasoconstricting activities of Dihydroergotamine.
LabetalolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dihydroergotamine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dihydroergotamine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Dihydroergotamine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Dihydroergotamine.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Dihydroergotamine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dihydroergotamine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dihydroergotamine.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Dihydroergotamine.
LepirudinThe serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Dihydroergotamine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Dihydroergotamine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dihydroergotamine.
LevobunololLevobunolol may increase the vasoconstricting activities of Dihydroergotamine.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Dihydroergotamine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Dihydroergotamine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Dihydroergotamine.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Dihydroergotamine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Dihydroergotamine.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Dihydroergotamine.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Dihydroergotamine.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Dihydroergotamine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Dihydroergotamine.
LinagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Linezolid.
LisinoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.
LisurideDihydroergotamine may increase the vasoconstricting activities of Lisuride.
LithiumThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dihydroergotamine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Dihydroergotamine.
LopinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Dihydroergotamine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Dihydroergotamine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dihydroergotamine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Dihydroergotamine.
LosartanThe metabolism of Losartan can be decreased when combined with Dihydroergotamine.
LovastatinThe metabolism of Dihydroergotamine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.
Lu AA21004Dihydroergotamine may increase the vasoconstricting activities of Lu AA21004.
LuliconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Dihydroergotamine.
LurasidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lurasidone.
MacitentanThe metabolism of Macitentan can be decreased when combined with Dihydroergotamine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dihydroergotamine.
MaprotilineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Dihydroergotamine.
MebanazineThe metabolism of Dihydroergotamine can be decreased when combined with Mebanazine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Dihydroergotamine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dihydroergotamine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Dihydroergotamine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Dihydroergotamine.
MelperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Melperone.
MephentermineDihydroergotamine may increase the hypertensive activities of Mephentermine.
MesoridazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.
MetaraminolDihydroergotamine may increase the hypertensive activities of Metaraminol.
MethadoneThe metabolism of Methadone can be decreased when combined with Dihydroergotamine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroergotamine.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Dihydroergotamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dihydroergotamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methotrimeprazine.
MethoxamineDihydroergotamine may increase the hypertensive activities of Methoxamine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Dihydroergotamine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Dihydroergotamine.
Methylene blueThe metabolism of Dihydroergotamine can be decreased when combined with Methylene blue.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Dihydroergotamine.
MetipranololMetipranolol may increase the vasoconstricting activities of Dihydroergotamine.
MetoclopramideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metoclopramide.
MetoprololMetoprolol may increase the vasoconstricting activities of Dihydroergotamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dihydroergotamine.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Dihydroergotamine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dihydroergotamine.
MianserinThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mianserin.
MianserinThe metabolism of Mianserin can be decreased when combined with Dihydroergotamine.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Dihydroergotamine.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Dihydroergotamine.
MidazolamThe metabolism of Midazolam can be decreased when combined with Dihydroergotamine.
MidodrineDihydroergotamine may increase the hypertensive activities of Midodrine.
MifepristoneThe serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Dihydroergotamine.
MilnacipranThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Dihydroergotamine.
MinaprineThe metabolism of Dihydroergotamine can be decreased when combined with Minaprine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Dihydroergotamine.
MirtazapineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mirtazapine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Dihydroergotamine.
MitotaneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dihydroergotamine.
MoclobemideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Moclobemide.
MoclobemideThe metabolism of Dihydroergotamine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Dihydroergotamine can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Dihydroergotamine.
MoexiprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Molindone.
MontelukastThe metabolism of Montelukast can be decreased when combined with Dihydroergotamine.
MorphineThe metabolism of Morphine can be decreased when combined with Dihydroergotamine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Dihydroergotamine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dihydroergotamine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may increase the vasoconstricting activities of Dihydroergotamine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Dihydroergotamine.
NafcillinThe serum concentration of Dihydroergotamine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dihydroergotamine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Dihydroergotamine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Dihydroergotamine.
NaratriptanDihydroergotamine may increase the vasoconstricting activities of Naratriptan.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Dihydroergotamine.
NCX 4016The serum concentration of Dihydroergotamine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Dihydroergotamine.
NelfinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Dihydroergotamine.
NetupitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Dihydroergotamine can be decreased when combined with Nevirapine.
NialamideThe metabolism of Dihydroergotamine can be decreased when combined with Nialamide.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Dihydroergotamine.
NicotineThe metabolism of Nicotine can be decreased when combined with Dihydroergotamine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Dihydroergotamine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Dihydroergotamine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Dihydroergotamine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dihydroergotamine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dihydroergotamine.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Dihydroergotamine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Dihydroergotamine.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine.
NitroglycerinDihydroergotamine may decrease the vasodilatory activities of Nitroglycerin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dihydroergotamine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Dihydroergotamine.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Dihydroergotamine.
NortriptylineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Nortriptyline.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Dihydroergotamine.
OctamoxinThe metabolism of Dihydroergotamine can be decreased when combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dihydroergotamine.
OlaparibThe metabolism of Dihydroergotamine can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.
OmapatrilatThe serum concentration of Dihydroergotamine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dihydroergotamine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Dihydroergotamine.
OndansetronThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Dihydroergotamine.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Dihydroergotamine.
OsanetantThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant.
OsimertinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Dihydroergotamine.
OtamixabanThe serum concentration of Dihydroergotamine can be increased when it is combined with Otamixaban.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Dihydroergotamine.
OxprenololOxprenolol may increase the vasoconstricting activities of Dihydroergotamine.
OxprenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Dihydroergotamine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Dihydroergotamine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Dihydroergotamine.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Dihydroergotamine.
PalbociclibThe serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Dihydroergotamine.
PaliperidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Dihydroergotamine.
PalonosetronPalonosetron may increase the serotonergic activities of Dihydroergotamine.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Dihydroergotamine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Dihydroergotamine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Dihydroergotamine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Dihydroergotamine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Dihydroergotamine.
PargylineThe metabolism of Dihydroergotamine can be decreased when combined with Pargyline.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Dihydroergotamine.
ParoxetineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.
PenbutololPenbutolol may increase the vasoconstricting activities of Dihydroergotamine.
PenbutololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Dihydroergotamine.
PentobarbitalThe metabolism of Dihydroergotamine can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Dihydroergotamine.
PergolideDihydroergotamine may increase the vasoconstricting activities of Pergolide.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Dihydroergotamine.
PerindoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Dihydroergotamine.
PerospironeThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Dihydroergotamine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroergotamine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Dihydroergotamine.
PhenelzineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenelzine.
PhenelzineThe metabolism of Dihydroergotamine can be decreased when combined with Phenelzine.
PheniprazineThe metabolism of Dihydroergotamine can be decreased when combined with Pheniprazine.
PhenobarbitalThe metabolism of Dihydroergotamine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Dihydroergotamine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Dihydroergotamine.
PhenoxypropazineThe metabolism of Dihydroergotamine can be decreased when combined with Phenoxypropazine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Dihydroergotamine.
PhenylephrineDihydroergotamine may increase the hypertensive activities of Phenylephrine.
PhenytoinThe metabolism of Dihydroergotamine can be increased when combined with Phenytoin.
PhosphoramidonThe serum concentration of Dihydroergotamine can be increased when it is combined with Phosphoramidon.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Dihydroergotamine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dihydroergotamine.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Dihydroergotamine.
PindololPindolol may increase the vasoconstricting activities of Dihydroergotamine.
PindololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Dihydroergotamine.
PipamperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipotiazine.
PirlindoleThe metabolism of Dihydroergotamine can be decreased when combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dihydroergotamine.
PivhydrazineThe metabolism of Dihydroergotamine can be decreased when combined with Pivhydrazine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Dihydroergotamine.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Dihydroergotamine.
PosaconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Dihydroergotamine.
PractololPractolol may increase the vasoconstricting activities of Dihydroergotamine.
PractololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Practolol.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Dihydroergotamine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Dihydroergotamine.
PrazepamThe metabolism of Prazepam can be decreased when combined with Dihydroergotamine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Dihydroergotamine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Dihydroergotamine.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Dihydroergotamine.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Dihydroergotamine.
PrimidoneThe metabolism of Dihydroergotamine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Dihydroergotamine can be increased when it is combined with Prinomastat.
ProcarbazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Dihydroergotamine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Dihydroergotamine.
PromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dihydroergotamine.
PropericiazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Dihydroergotamine.
PropranololPropranolol may increase the vasoconstricting activities of Dihydroergotamine.
PropranololThe metabolism of Propranolol can be decreased when combined with Dihydroergotamine.
ProtriptylineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dihydroergotamine.
PRX-00023Dihydroergotamine may increase the vasoconstricting activities of PRX-00023.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Dihydroergotamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Dihydroergotamine.
QuetiapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Dihydroergotamine.
QuinaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.
QuinidineThe metabolism of Quinidine can be decreased when combined with Dihydroergotamine.
QuinineThe metabolism of Quinine can be decreased when combined with Dihydroergotamine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Dihydroergotamine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Dihydroergotamine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Dihydroergotamine.
RamiprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Dihydroergotamine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dihydroergotamine.
RanolazineThe metabolism of Dihydroergotamine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Rasagiline.
RasagilineThe metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Dihydroergotamine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Dihydroergotamine.
RemikirenThe serum concentration of Dihydroergotamine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Dihydroergotamine.
ReserpineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Reserpine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Dihydroergotamine.
RifabutinThe metabolism of Dihydroergotamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Dihydroergotamine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Dihydroergotamine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dihydroergotamine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Dihydroergotamine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Dihydroergotamine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Dihydroergotamine.
RisperidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Risperidone.
RitonavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Dihydroergotamine.
RivaroxabanThe serum concentration of Dihydroergotamine can be increased when it is combined with Rivaroxaban.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Dihydroergotamine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Dihydroergotamine.
RizatriptanDihydroergotamine may increase the vasoconstricting activities of Rizatriptan.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Dihydroergotamine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Dihydroergotamine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Dihydroergotamine.
RopiniroleDihydroergotamine may increase the vasoconstricting activities of Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Dihydroergotamine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Dihydroergotamine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Dihydroergotamine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.
SafrazineThe metabolism of Dihydroergotamine can be decreased when combined with Safrazine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dihydroergotamine.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dihydroergotamine.
SaquinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Dihydroergotamine.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dihydroergotamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Dihydroergotamine.
SelexipagThe metabolism of Selexipag can be decreased when combined with Dihydroergotamine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Dihydroergotamine.
SertindoleThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertindole.
SertralineThe metabolism of Sertraline can be decreased when combined with Dihydroergotamine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dihydroergotamine.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Dihydroergotamine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Dihydroergotamine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Dihydroergotamine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.
SiltuximabThe serum concentration of Dihydroergotamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dihydroergotamine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Dihydroergotamine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Dihydroergotamine.
SitagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Sitagliptin.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Dihydroergotamine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dihydroergotamine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Dihydroergotamine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Dihydroergotamine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.
SotalolSotalol may increase the vasoconstricting activities of Dihydroergotamine.
SotalolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dihydroergotamine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dihydroergotamine.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Dihydroergotamine.
SpiraprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Dihydroergotamine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Dihydroergotamine can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Dihydroergotamine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Dihydroergotamine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Dihydroergotamine.
SulfisoxazoleThe metabolism of Dihydroergotamine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Dihydroergotamine.
SumatriptanDihydroergotamine may increase the vasoconstricting activities of Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Dihydroergotamine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Dihydroergotamine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dihydroergotamine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dihydroergotamine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Dihydroergotamine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Dihydroergotamine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Dihydroergotamine.
TapentadolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tapentadol.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Dihydroergotamine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Dihydroergotamine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dihydroergotamine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dihydroergotamine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Dihydroergotamine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Dihydroergotamine.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Dihydroergotamine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Dihydroergotamine.
TemocaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Temocapril.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Dihydroergotamine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Dihydroergotamine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Dihydroergotamine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Dihydroergotamine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Dihydroergotamine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Dihydroergotamine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Dihydroergotamine.
ThioproperazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioridazine.
ThiorphanThe serum concentration of Dihydroergotamine can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Dihydroergotamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Dihydroergotamine.
TianeptineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Tianeptine.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Dihydroergotamine.
TiclopidineThe metabolism of Dihydroergotamine can be decreased when combined with Ticlopidine.
TimololTimolol may increase the vasoconstricting activities of Dihydroergotamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Dihydroergotamine.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Dihydroergotamine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Dihydroergotamine.
TipranavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Dihydroergotamine.
TocilizumabThe serum concentration of Dihydroergotamine can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Dihydroergotamine.
ToloxatoneThe metabolism of Dihydroergotamine can be decreased when combined with Toloxatone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Dihydroergotamine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dihydroergotamine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dihydroergotamine.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Dihydroergotamine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dihydroergotamine.
TramadolThe metabolism of Tramadol can be decreased when combined with Dihydroergotamine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroergotamine.
TrandolaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineThe metabolism of Dihydroergotamine can be decreased when combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tranylcypromine.
TranylcypromineThe metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Dihydroergotamine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Dihydroergotamine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroergotamine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Dihydroergotamine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Dihydroergotamine.
TriazolamThe metabolism of Triazolam can be decreased when combined with Dihydroergotamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Dihydroergotamine.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Dihydroergotamine.
TrimipramineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Dihydroergotamine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Dihydroergotamine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Dihydroergotamine.
UbenimexThe serum concentration of Dihydroergotamine can be increased when it is combined with Ubenimex.
UdenafilThe metabolism of Udenafil can be decreased when combined with Dihydroergotamine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dihydroergotamine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dihydroergotamine.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Dihydroergotamine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Dihydroergotamine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Dihydroergotamine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Dihydroergotamine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dihydroergotamine.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Dihydroergotamine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Dihydroergotamine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Dihydroergotamine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Dihydroergotamine.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Dihydroergotamine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Dihydroergotamine.
VilazodoneDihydroergotamine may increase the vasoconstricting activities of Vilazodone.
VildagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Vildagliptin.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Dihydroergotamine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dihydroergotamine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dihydroergotamine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Dihydroergotamine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Dihydroergotamine.
VoriconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Dihydroergotamine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dihydroergotamine.
VortioxetineDihydroergotamine may increase the vasoconstricting activities of Vortioxetine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Dihydroergotamine.
XimelagatranThe serum concentration of Dihydroergotamine can be increased when it is combined with Ximelagatran.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Dihydroergotamine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Dihydroergotamine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Dihydroergotamine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Dihydroergotamine.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Dihydroergotamine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Dihydroergotamine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Dihydroergotamine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dihydroergotamine.
ZolmitriptanDihydroergotamine may increase the vasoconstricting activities of Zolmitriptan.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Dihydroergotamine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Dihydroergotamine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Dihydroergotamine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Dihydroergotamine.
ZotepineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zotepine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE: Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. [PubMed:9605573 ]
  3. Buzzi MG, Moskowitz MA: The trigemino-vascular system and migraine. Pathol Biol (Paris). 1992 Apr;40(4):313-7. [PubMed:1379707 ]
  4. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA: 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res. 1992 Jun 26;583(1-2):137-49. [PubMed:1324091 ]
  5. Silberstein SD, McCrory DC: Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144-66. [PubMed:12558771 ]
  6. Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM: "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54. [PubMed:1407010 ]
  7. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Willems EW, Trion M, De Vries P, Heiligers JP, Villalon CM, Saxena PR: Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol. 1999 Jul;127(5):1263-71. [PubMed:10455274 ]
  2. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
  3. Buzzi MG, Moskowitz MA: Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991 Sep;11(4):165-8. [PubMed:1660351 ]
  4. Yu XJ, Waeber C, Castanon N, Scearce K, Hen R, Macor JE, Chauveau J, Moskowitz MA: 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol. 1996 May;49(5):761-5. [PubMed:8622623 ]
  5. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [PubMed:9650800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L: Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. Epub 2003 Aug 11. [PubMed:12970106 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23